Investor Relations, Email: ir@nuvoresearch.comCopyright CNW Group 2015
Nuvo Research® Announces Intention to Split Into Two Publicly Traded Companies
On 6ix: 6ix.com/news/nuvo-researchandxae-announces-intention-to-split-into-two-publicly-traded-companies
View original source (CNW)Nuvo Pharmaceuticals Inc on 6ix
Story so far
Earlier from Nuvo Pharmaceuticals
- Nuvo Research® Announces U.S. Patent for Topical Foamed Formulations that Include DMSO
- Nuvo Research® Announces Grant of United States Patent for Topical Onychomycosis Formulation
- Nuvo Research® Announces 2015 Second Quarter Results
- Nuvo Research® Provides Update on International Licensing of Pennsaid® 2%
- Nuvo Research® Receives Health Canada Approval to Conduct New WF10(TM) Phase 2 Trial
Later from Nuvo Pharmaceuticals
- Nuvo Research® Announces Appointment to its Board of Directors
- Nuvo Research Announces Successful Pennsaid®2% Phase 3 Trial for Russia
- Nuvo Research® Announces 2015 Third Quarter Results
- Nuvo Research® Announces TSX Conditional Approval to List Crescita Therapeutics Inc.
- Nuvo Research® Announces Acceleration of Expiry Date of Outstanding Warrants
Follow Nuvo Pharmaceuticals into a list and get an email when it puts out news.
Follow Nuvo Pharmaceuticals